The Pharmaceutical Industry and the Controlled Substances Act – A Distinct Breed of Monitorship

Reprinted from: Global Investigations Review | June 9, 2020

Cadwalader's Jodi Avergun, Todd Blanche and Christian Larson provide insights into the practice of imposing monitorships on pharmaceutical companies that are settling alleged or admitted violations of the Controlled Substances Act for Global Investigations Review.

To read, click here.

The above is an extract from the second edition of "The Guide to Monitorships" published by Global Investigations Review. The whole publication is available here.

CadwaladerNews

To assist individuals in working from home during the coronavirus social-distancing period, Cadwalader is providing clients and friends free access to our legal research platform, the Cadwalader Cabinet.